An observational study of pleiotropy and penetrance of amyotrophic lateral sclerosis associated with CAG-repeat expansion of ATXN2
Open Access
- 16 February 2025
- journal article
- research article
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 33 (9) , 1106-1112
Abstract
Spinocerebellar ataxia type 2 (SCA2) and amyotrophic lateral sclerosis (ALS) are both associated with a CAG-repeat expansion in ATXN2 and with TDP-43-positive neuronal cytoplasmic inclusions. The two disorders have been viewed as distinct entities, where an intermediate length expansion of 31-33 CAG-repeats is associated with sporadic ALS and a full length expansion of ≥34 CAG-repeats is associated with SCA2. We report the clinical phenotype of ATXN2-positive patients and their relatives, identified in three specialist ALS clinics, which force a reconsideration of this dichotomy. We also report the frequency of ATXN2 expansions in two large cohorts of ALS patients and in a population-matched cohort of controls. We report ten cases of familial ALS in which disease is associated with either an intermediate or a full-length ATXN2 CAG-repeat expansion. Pedigrees and patients feature additional phenotypes including parkinsonism, dementia and essential tremor (ET). We conclude that CAG-repeat expansions in ATXN2 exhibit pleiotropy and are associated with a disease spectrum that includes ALS, SCA2, and parkinsonism; to recognise this complexity we propose the new term ‘ATXN2-related neurodegeneration’. We also observed sporadic ALS associated with full-length expansions. We conclude that ATXN2 CAG-repeat expansions, irrespective of length, should be considered a risk factor for ALS. Interrupted CAG-repeats were associated with an ALS phenotype in our data but we also identified ALS cases with uninterrupted expansions. Our findings have relevance for researchers, patients and families linked to CAG-repeat expansions in ATXN2.Keywords
All Related Versions
Funding Information
- Wellcome Trust (216596/Z/19/Z)
- Motor Neurone Disease Association (899-792, 974-797, 972-797)
- U.S. Department of Health & Human Services | National Institutes of Health (U54 NS092091)
- ZonMw
- Fondation Thierry Latran
- Cure for MND Foundation
This publication has 23 references indexed in Scilit:
- ATAXIN-2 intermediate-length polyglutamine expansions elicit ALS-associated metabolic and immune phenotypesNature Communications, 2024
- Detection of ATXN2 Expansions in an Exome Dataset: An Underdiagnosed Cause of ParkinsonismMovement Disorders Clinical Practice, 2023
- The value of testing for ATXN2 intermediate repeat expansions in routine clinical practice for amyotrophic lateral sclerosisEuropean Journal of Human Genetics, 2022
- Simultaneous ALS and SCA2 associated with an intermediate-length ATXN2 CAG-repeat expansionAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020
- Project MinE: study design and pilot analyses of a large-scale whole-genome sequencing study in amyotrophic lateral sclerosisEuropean Journal of Human Genetics, 2018
- The Multiple Faces of Spinocerebellar Ataxia type 2Annals of Clinical and Translational Neurology, 2017
- ATXN2 trinucleotide repeat length correlates with risk of ALSNeurobiology of Aging, 2017
- Amyotrophic Lateral Sclerosis Risk for Spinocerebellar Ataxia Type 2ATXN2CAG Repeat AllelesJAMA Neurology, 2014
- FTLD-ALS of TDP-43 type and SCA2 in a family with a full ataxin-2 polyglutamine expansionActa Neuropathologica, 2014
- Spinocerebellar ataxia type 2 (SCA2) is associated with TDP-43 pathologyActa Neuropathologica, 2011